1-3 of 3
A. Giagounidis, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Risk Factors for Disease Progression in del(5q) MDS Patients Treated with Lenalidomide.

Aristoteles A. Giagounidis, MD, Sabine Haase, Uwe Platzbecker, MD PhD, Ulrich Germing, MD PhD, Vera Lohrbacher, Gerhard Ehninger, MD PhD, Carlo Aul, MD PhD
Journal: Blood
Blood (2007) 110 (11): 1460.
https://doi.org/10.1182/blood.V110.11.1460.1460
Published: 2007
Journal Articles

Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study.

Pierre Fenaux, MD, G.J. Mufti, MD, V. Santini, MD, C. Finelli, MD, A. Giagounidis, MD, R. Schoch, MD, A.F. List, MD, S.D. Gore, MD, J.F. Seymour, MD, E. Hellstrom-Lindberg, MD, J.M. Bennett, MD, J.C. Byrd, MD, J.T. Backstrom, MD, L.S. Zimmerman, BSN, D.R. McKenzie, MS, C.L. Beach, PharmD, L.R. Silverman, MD
Journal: Blood
Blood (2007) 110 (11): 817.
https://doi.org/10.1182/blood.V110.11.817.817
Published: 2007
Journal Articles

Lenalidomide Is Likely To Improve Overall Survival in Patients with del(5q) Myelodysplastic Syndrome with a Complex Karyotype.

Aristoteles A. Giagounidis, MD, Sabine Haase, Ulrich Germing, MD PhD, Gundula Göhring-Michaelsen, Brigitte Schlegelberger, MD PhD, Carlo Aul, MD PhD
Journal: Blood
Blood (2006) 108 (11): 4860.
https://doi.org/10.1182/blood.V108.11.4860.4860
Published: 2006